Milestone payment keeps the trigger on Piramal Lifesciences: Rajesh Jain

Rajesh Jain, Director, Research & Sales, Mview: Marvadi Shares & Finance in a chat with ET Now talks about Piramal Lifesciences.

Piramal Lifesciences, this is pure play, commercialisation of drug discovery, everything they have is on clinical II, it is not even in clinical III. Do you think perhaps what the market is factoring is some kind of a milestone payment of the sale of a molecule because that’s pretty much all we are running on, there is not heard anything else from the company?

I would second that but we must accept that the company has a fairly good critical mass in terms of various products under testing in various phases and milestone payment is what keeps the trigger on this counter.